Report : Asia Pacific Pulmonary Function Testing Systems Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Cart-Based PFT Systems and Stationery PFT Systems), Test Type (Spirometry, Lung Volume, Gas Exchange Testing, Maximum Voluntary Ventilation, Oxygen Titration Test, and Others), Component (Hardware, Software, and Services), Application (Chronic Obstructive Pulmonary Disorder, Asthma, Chronic Shortness of Breath, Restrictive Lung Disease, and Others), and End User (Hospitals, Specialty Clinics, and Diagnostic Laboratories)
At 7.1% CAGR, the Asia Pacific Pulmonary Function Testing Systems Market is speculated to be worth US$ 87.40 million by 2028, says Business Market Insights
According to Business Market Insights research, the Asia Pacific pulmonary function testing systems market was valued at US$ 58.00 million in 2022 and is expected to reach US$ 87.40 million by 2028, registering a CAGR of 7.1% from 2022 to 2028. Rising incidence of lung-related disorders and workplace pulmonary function testing systems are the critical factors attributed to the Asia Pacific pulmonary function testing systems market expansion.
The PFT systems provide accurate results, particularly lung volume, capacity, rates of flow, and gas exchange. Additionally, PFT systems utilization assists in assessing treatment for asthma, emphysema, and other chronic lung problems. Through the assessment of lung volumes, capacities, rates of flow, and gas exchange, PFTs can provide information that can be evaluated by physicians to help diagnose certain lung disorders effectively and decide the right treatment for patients. Further, PFTs are noninvasive procedures and are usually recommended by physicians for patients with no hospital stay. Commercial pulmonary function testing systems available in the market include spirometry. Spirometry testing is useful for determining if the patient is suffering from lung disease, type of lung disease, progression of the lung disease, and impairment of lung disease. Spirometry measures airflow and can evaluate a broad range of lung diseases among patients. Thus, the rising incidence of lung-related disorders is fueling the use of pulmonary function testing systems and thus it is driving the growth of Asia Pacific pulmonary function testing systems market.
On the contrary, risk of cross-contamination and lack of skilled professionals hampers the Asia Pacific pulmonary function testing systems market.
Based on type, the Asia Pacific pulmonary function testing systems market is segmented into cart-based pft systems and stationery pft systems. The cart-based pft systems segment held 77.7% share of Asia Pacific pulmonary function testing systems market in 2022, amassing US$ 45.05 million. It is projected to garner US$ 68.94 million by 2028 to expand at 7.3% CAGR during 2022–2028.
Based on test type, the Asia Pacific pulmonary function testing systems market is segmented into spirometry, lung volume, gas exchange testing, maximum voluntary ventilation, oxygen titration test, and others. The spirometry segment held 44.0% share of Asia Pacific pulmonary function testing systems market in 2022, amassing US$ 25.54 million. It is projected to garner US$ 39.03 million by 2028 to expand at 7.3% CAGR during 2022–2028.
Based on component, the Asia Pacific pulmonary function testing systems market is segmented into hardware, software, and services. The hardware segment held 41.9% share of Asia Pacific pulmonary function testing systems market in 2022, amassing US$ 24.31 million. It is projected to garner US$ 36.36 million by 2028 to expand at 6.9% CAGR during 2022–2028.
Based on application, the Asia Pacific pulmonary function testing systems market is segmented into chronic obstructive pulmonary disorder, asthma, chronic shortness of breath, restrictive lung disease, and others. The chronic obstructive pulmonary disorder segment held 35.6% share of Asia Pacific pulmonary function testing systems market in 2022, amassing US$ 20.66 million. It is projected to garner US$ 31.62 million by 2028 to expand at 7.4% CAGR during 2022–2028.
Based on end-user, the Asia Pacific pulmonary function testing systems market is segmented into hospitals, specialty clinics, and diagnostic laboratories. The hospitals segment held 47.0% share of Asia Pacific pulmonary function testing systems market in 2022, amassing US$ 27.24 million. It is projected to garner US$ 41.86 million by 2028 to expand at 7.4% CAGR during 2022–2028.
Based on country, the Asia Pacific pulmonary function testing systems market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. Our regional analysis states that China captured 29.3% share of Asia Pacific pulmonary function testing systems market in 2022. It was assessed at US$ 16.97 million in 2022 and is likely to hit US$ 25.30 million by 2028, exhibiting a CAGR of 6.9% during the forecast period.
Key players dominating the Asia Pacific pulmonary function testing systems market are COSMED Srl; KoKo PFT Ltd; MGC Diagnostics Corp; ndd Medical Technologies Inc; PulmOne Advanced Medical Devices Ltd; Schiller AG; and Vyaire Medical Inc, among others.
- In April 2021; Vyaire Medical announced the global launch of ArtiQ.PFT, an automated tool driven by artificial intelligence that instantly interprets pulmonary function tests (PFTs). ArtiQ.PFT is the first cloud-based PFT-solution that leverages artificial intelligence.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com